Lipoproteins as biomarkers and therapeutic targets in the setting of acute coronary syndrome. [Review]
Lipoproteins as biomarkers and therapeutic targets in the setting of acute coronary syndrome. [Review]
- 2014
Available online from MWHC library: 1953 - present
The period following an acute coronary syndrome (ACS) represents a critical time frame with a high risk for recurrent events and death. The pathogenesis of this increase in clinical cardiovascular disease events after ACS is complex, with molecular mechanisms including increased thrombosis and inflammation. Dyslipoproteinemia is common in patients with ACS and predictive of recurrent cardiovascular disease events after presentation with an ACS event. Although randomized clinical trials have provided fairly convincing evidence that high-dose statins reduce the risk of recurrent cardiovascular events after ACS, there remain questions about how aggressively to reduce low-density lipoprotein cholesterol levels in ACS. Furthermore, no other lipid-related interventions have yet been proven to be effective in reducing major cardiovascular events after ACS. Here, we review the relationship of lipoproteins as biomarkers to cardiovascular risk after ACS, the evidence for lipid-targeted interventions, and the potential for novel therapeutic approaches in this arena. 2014 American Heart Association, Inc.
English
0009-7330
*Acute Coronary Syndrome/dt [Drug Therapy]
*Acute Coronary Syndrome/me [Metabolism]
*Hydroxymethylglutaryl-CoA Reductase Inhibitors/tu [Therapeutic Use]
*Lipoproteins/bl [Blood]
Acute Coronary Syndrome/ep [Epidemiology]
Biological Markers/bl [Blood]
Coronary Artery Disease/dt [Drug Therapy]
Coronary Artery Disease/ep [Epidemiology]
Coronary Artery Disease/me [Metabolism]
Humans
Risk Factors
MedStar Health Research Institute
Journal Article
Review
Available online from MWHC library: 1953 - present
The period following an acute coronary syndrome (ACS) represents a critical time frame with a high risk for recurrent events and death. The pathogenesis of this increase in clinical cardiovascular disease events after ACS is complex, with molecular mechanisms including increased thrombosis and inflammation. Dyslipoproteinemia is common in patients with ACS and predictive of recurrent cardiovascular disease events after presentation with an ACS event. Although randomized clinical trials have provided fairly convincing evidence that high-dose statins reduce the risk of recurrent cardiovascular events after ACS, there remain questions about how aggressively to reduce low-density lipoprotein cholesterol levels in ACS. Furthermore, no other lipid-related interventions have yet been proven to be effective in reducing major cardiovascular events after ACS. Here, we review the relationship of lipoproteins as biomarkers to cardiovascular risk after ACS, the evidence for lipid-targeted interventions, and the potential for novel therapeutic approaches in this arena. 2014 American Heart Association, Inc.
English
0009-7330
*Acute Coronary Syndrome/dt [Drug Therapy]
*Acute Coronary Syndrome/me [Metabolism]
*Hydroxymethylglutaryl-CoA Reductase Inhibitors/tu [Therapeutic Use]
*Lipoproteins/bl [Blood]
Acute Coronary Syndrome/ep [Epidemiology]
Biological Markers/bl [Blood]
Coronary Artery Disease/dt [Drug Therapy]
Coronary Artery Disease/ep [Epidemiology]
Coronary Artery Disease/me [Metabolism]
Humans
Risk Factors
MedStar Health Research Institute
Journal Article
Review